Data as of November 13, 2026

Biktarvy 30-120-15 mg Tablet

BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE

Brand: Biktarvy

Acquisition price (NADAC) is as of October 21, 2026. Medicaid reimbursement figures are from 2024, the most recent year in CMS's published claims data. The two are not contemporaneous — treat any comparison as directional, not exact.

Price per fill

NADAC (acquisition)
$4,139.79/ fill$136.63 / EA
VA Big4
$3,035.42/ fill$100.18 / EA
Medicaid FFS
$4,024.95/ fill
Medicaid MCO
$3,904.63/ fill

Sources: cms/nadac:price-ladder · va/fss-drug-prices:normalized · cms/sdud

What's in the reimbursement

Ingredient cost (30.3 units/fill)$4,139.79
Dispensing fee & other (state-fixed, not margin)-$114.84
Total reimbursed per fill$4,024.95

The gap above stays roughly flat across drugs regardless of acquisition cost — that's the professional dispensing fee, a fixed per-fill amount the state pays every pharmacy, not a markup.

Medicaid volume backing this card: 4 fee-for-service states, 11 managed-care states.

Full methodology and source columns: /tools/drug-prices/methodology

Sources: acquisition prices from CMS's National Average Drug Acquisition Cost survey, effective 2026-10-28; utilisation from CMS State Drug Utilization Data, 2024; Cost Plus Drugs prices from their published price list. NADAC and SDUD vintages differ. Every number links to how it was calculated. Full methodology